| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
10.91(B) |
| Last
Volume: |
1,933,966 |
Avg
Vol: |
1,913,064 |
| 52
Week Range: |
$56.27 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
103,519 |
108,398 |
180,881 |
290,334 |
| Total Sell Value |
$6,219,303 |
$6,570,910 |
$12,429,896 |
$18,676,003 |
| Total People Sold |
10 |
10 |
11 |
11 |
| Total Sell Transactions |
49 |
52 |
65 |
100 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Clancy Paul J |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,599 |
14,701 |
|
- |
|
| Petrovic Shacey |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,599 |
17,562 |
|
- |
|
| Sebelius Kathleen |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,599 |
24,999 |
|
- |
|
| Jacquet Pierre |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
4,580 |
23,576 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2023-05-26 |
4 |
AS |
$80.62 |
$161,240 |
D/D |
(2,000) |
51,913 |
|
-21% |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2023-05-10 |
4 |
AS |
$80.00 |
$400,000 |
D/D |
(5,000) |
6,423 |
|
-4% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-05-10 |
4 |
AS |
$80.00 |
$486,960 |
D/D |
(6,087) |
80,314 |
|
-4% |
|
| Herriott James |
General Counsel |
• – – |
2023-05-10 |
4 |
AS |
$79.85 |
$103,805 |
D/D |
(1,300) |
8,564 |
|
-4% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2023-05-01 |
4 |
A |
$30.02 |
$21,284 |
D/D |
709 |
1,208,015 |
|
- |
|
| Cunningham Everett |
Chief Commercial Officer |
• – – |
2023-05-01 |
4 |
A |
$30.02 |
$21,284 |
D/D |
709 |
23,412 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2023-05-01 |
4 |
A |
$30.02 |
$21,284 |
D/D |
709 |
30,210 |
|
- |
|
| Herriott James |
General Counsel |
• – – |
2023-05-01 |
4 |
A |
$30.02 |
$19,213 |
D/D |
640 |
9,864 |
|
- |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-05-01 |
4 |
AS |
$63.78 |
$63,780 |
D/D |
(1,000) |
86,401 |
|
24% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-04-30 |
4 |
A |
$30.02 |
$21,284 |
D/D |
709 |
87,401 |
|
- |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-04-03 |
4 |
AS |
$67.19 |
$67,190 |
D/D |
(1,000) |
86,692 |
|
23% |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2023-03-03 |
4 |
AS |
$65.00 |
$325,000 |
D/D |
(5,000) |
11,423 |
|
46% |
|
| Cunningham Everett |
Chief Commercial Officer |
• – – |
2023-03-01 |
4 |
AS |
$62.01 |
$224,972 |
D/D |
(3,628) |
22,703 |
|
53% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-03-01 |
4 |
AS |
$62.00 |
$62,000 |
D/D |
(1,000) |
87,692 |
|
53% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-02-28 |
4 |
AS |
$61.12 |
$178,715 |
D/D |
(2,924) |
88,692 |
|
52% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2023-02-28 |
4 |
AS |
$61.12 |
$258,721 |
D/D |
(4,233) |
29,241 |
|
52% |
|
| Coward D Scott |
Director |
– • – |
2023-02-28 |
4 |
AS |
$61.12 |
$253,831 |
D/D |
(4,153) |
32,775 |
|
52% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2023-02-28 |
4 |
AS |
$61.12 |
$636,626 |
D/D |
(10,416) |
1,207,306 |
|
52% |
|
| Herriott James |
General Counsel |
• – – |
2023-02-28 |
4 |
AS |
$59.98 |
$134,453 |
D/D |
(2,225) |
9,224 |
|
52% |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2023-02-28 |
4 |
AS |
$59.98 |
$411,872 |
D/D |
(6,832) |
16,423 |
|
52% |
|
| Baranick Brian |
Gen. Mgr., Precision Oncology |
• – – |
2023-02-28 |
4 |
AS |
$61.12 |
$118,084 |
D/D |
(1,932) |
7,509 |
|
52% |
|
777 Records found
|
|
Page 5 of 32 |
|
|
1.94 (3.06%) 
